Physician profile
Romnee Reyes
NPI 1912411000
$374.60
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $250.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $92.43 | 2021-2022 | |
| Amarin Pharma, INC. | $71.32 | 2021-2022 | |
| Abbvie INC. | $49.93 | 2021-2022 | |
| Astellas Pharma US INC | $35.26 | 2022 | |
| Glaxosmithkline, LLC. | $31.14 | 2021-2022 | |
| Lilly USA, LLC | $27.52 | 2022 | |
| Dynavax Technologies Corporation | $19.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.31 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.47 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romnee Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.